We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients (CARMEN)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01362933
First Posted: June 1, 2011
Last Update Posted: March 6, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
Centre Hospitalier Universitaire, Amiens
Groupe Francophone Thrombose et Cancer (GFTC)
University Hospital, Grenoble
Information provided by (Responsible Party):
Floralis
May 25, 2011
June 1, 2011
March 6, 2015
May 2011
January 2012   (Final data collection date for primary outcome measure)
Evaluation of the adherence to recommendations of VTE treatment in cancer patients [ Time Frame: At baseline (J0) ]
Proportion of patients treated for evolutive VTE according to international recommandations Patients could be hospitalised or could be out patient
Same as current
Complete list of historical versions of study NCT01362933 on ClinicalTrials.gov Archive Site
  • Evaluation of VTE disease according to cancer diagnosis (proportion of SVT (Superficial Venous Thrombosis), DVT (Deep Venous Thrombosis), PE (Pulmonary Embolism) [ Time Frame: At baseline (J0) ]
    Percentage of VTE (PE,DVT,SVT)and cancer type
  • Proportion of asymptomatic VTE disease for this population [ Time Frame: At baseline (J0) ]
    percentage of VTE and cancer status (local, metastatic)
  • Feasibility of self injections for VTE treatment in cancer patients. [ Time Frame: At baseline (J0) ]
    percentage of patients practising self injections
  • Proportion of patients with catheter thrombosis [ Time Frame: At baseline (J0) ]
    Percentage of patients receiving novel cancer therapies
Same as current
Not Provided
Not Provided
 
National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients
National Evaluation of the Adherence to Recommendations of VTE Treatment in Cancer Patients
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months. International recommendations have diffused this option.It is necessary to evaluate the compliance of physicians to this treatment by measuring the number of patients with cancer treated with long term use of LMWH.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months
  • Neoplasms
  • Venous Thromboembolism
Procedure: VTE treatment in cancer patient description
proportion of patients treated for evolutive VTE according to international recommendations
VTE treatment in cancer patient
All patients with cancer present in the clinic, hospital, out patient diagnosed with a VTE during the 6 previous months.
Intervention: Procedure: VTE treatment in cancer patient description

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
502
July 2012
January 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

All patients with cancer present in the clinic, hospital, out patients diagnosed with a VTE during the 6 previous months. VTE can be symptomatic or asymptomatic, can be located close to a central line, and of any type (DVT, PE, SVT)

Exclusion Criteria:

  • Patient already included in a trial studying antithrombotic therapy
  • Patient refusing the study
  • Patient under 18 and/or not competent to give informed consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
France
 
 
NCT01362933
Version N°2.0 du 21/03/2011
No
Not Provided
Not Provided
Floralis
Floralis
  • Centre Hospitalier Universitaire, Amiens
  • Groupe Francophone Thrombose et Cancer (GFTC)
  • University Hospital, Grenoble
Principal Investigator: Marie-Antoinette SEVESTRE, MD Centre Hospitalier Universitaire, Amiens
Study Director: Dominique FARGE BANCEL, MD GFTC
Study Director: Jean Luc BOSSON, MD University Hospital, Grenoble
Floralis
March 2015